FDA Grants Breakthrough Therapy Designation to Zongertinib Tablets in NSCLC
Results from the Beamion-LUNG 1 trial showed an ORR of 75% for patients with HER2+ NSCLC treated with zongertinib.
Chemo/Radiation Did Not Yield Increased Pelvic Malignancies in Rectal Cancer
In patients with rectal cancer, the median OS was 12 years in the chemotherapy and radiation therapy group vs 24 years in the chemotherapy alone group.
Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703
Researchers from the BMT CTN reported that posttransplant cyclophosphamide-based GVHD prophylaxis significantly improves outcomes for adults aged 70 years and older undergoing allo-HCT.
Reprogramming the Neuroblastoma Tumor Immune Microenvironment to Enhance GPC2 CAR T-cells
Researchers at the CHOP have developed a new strategy to improve the effectiveness of GPC2-directed CAR T-cell therapy in neuroblastoma by reprogramming the tumor immune microenvironment.
Stereotactic Ablative Radiotherapy Achieves Local Control on Bone Metastases
Results from a phase 2 trial showed a 1-year local control rate of 93.1% with SABR in patients with solid tumors who have uncomplicated bone metastases.
Urine Glycosaminoglycan Scores Show High Sensitivity to Detect ccRCC
External validation will be assessed in cohort 2 of the AURORAX-0087A trial to improve recurrence detection for clear cell renal cell carcinoma.
DART Therapy Exhibits Greater Tolerability in Oropharyngeal SCC
The cumulative chronic grade 3 or higher toxicity rate was 3% in patients treated with de-escalated adjuvant radiotherapy vs 11% with standard of care therapy.
Lung Oncologists Take to Social Media to Highlight Impactful WCLC Abstracts
Leveraging #WCLC25, lung oncologists spoke about the presentations they’re most looking forward to at the upcoming conference.
In the News: Top FDA Meetings, Decisions, and Actions in Cancer Care
Updates on treatments like vusolimogene oderparepvec for advanced melanoma, and novel therapies have been provided by the FDA.
Interferon Alpha Nasal Spray Decreases COVID-19 Risk in Those With Cancer
Only 2 patients died in the phase 3 trial evaluating interferon-alpha in adult patients with cancer, but were deemed unrelated to study treatment.
Encorafenib Triplet Exhibits Early Efficacy in MSS BRAFV600E Metastatic CRC
Decreased MAPK signature and increased interferon gamma response signature were associated with sustained treatment benefit on serial evRNA profiling.
FDA Approves 2 Additional Denosumab Biosimilars in Prior Indications
The denosumab biosimilars have been approved based on review of a comprehensive data package that showed no meaningful differences vs the already approved agents.
Recapping A Quarter Decade of Chronic Myeloid Leukemia Therapy
Jorge Cortes, MD, believes that, despite the rapid improvements made in CML treatment, there is always more to be done to help patients.
Managing Dose Reductions With TAS-102 Therapy in Colorectal Cancer
The most common toxicity associated with TAS-102 was neutropenia, with grade 3 events occurring in 73.3% of patients with colorectal cancer.
KIM-1, Blood-Based Biomarkers May Show Promise in Kidney Cancer
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
TAS-102 Achieves ctDNA Clearance, Improves DFS in Colorectal Cancer
“…I like TAS-102 as an agent, but we need better drugs than we have right now to clear ctDNA and cure patients,” said Hornstein, MD, PhD.
Man Up? The Truth About Men's Health After Cancer
Christian J. Nelson, PhD, dives into the complexities of sexual health concerns with men following cancer treatment, specifically with genitourinary cancers.
Exa-cel Exhibits Meaningful HRQoL Benefit in Severe Sickle Cell Disease
The overall pain experience among adult and pediatric patients with severe sickle cell disease significantly improved after exa-cel infusion.
Male Pediatric Patients Have Lower Self-Reported Symptom Burden From Cancer
Pediatric patients self-reported symptom burden using the SSPedi tool, which observed symptom burden from baseline, 4 weeks, and 8 weeks.
Addressing Limited Treatment Options for Refractory CRC
The phase 2 INTERCEPT-TT trial showed that TAS-102 induced ctDNA clearance following adjuvant chemotherapy in patients with colorectal cancer.
Chemoradiation Shows Long-Term Clinical Benefit in High-Risk Gastric Cancer
The incidence of grade 3 to 4 acute toxicities was similar in patients with high-risk gastric cancer treated with chemoradiation or chemotherapy.
Chemotherapy Confers No Survival Benefit in Older Breast Cancer Population
Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.
Frontline Immunotherapy May Offer Best Chance to Cure Kidney Cancer
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Navigating the Mental and Emotional Landscape of Cancer
Boris M. Kiselev, MD, discusses the role of psycho-oncology in comprehensive cancer care, addressing barriers and offering a vision for the field’s future.
Dendritic Cell Vaccine Shows Preliminary Activity in Advanced HCC
The addition of dendritic cells to TACE in patients with intermediate-stage HCC did not significantly increase the incidence or severity of AEs.
Staying Current: Your Guide to August 2025 Oncology Research
An oncologist’s passion for breast surgery, novel cancer vaccines in gastrointestinal cancers, and emerging actionable biomarkers for lung cancer were all covered in August.
Sonrotoclax Meets Primary ORR End Point in Mantle Cell Lymphoma
The safety profile of sonrotoclax was generally well-tolerated, and emergent toxicities were manageable in patients with mantle cell lymphoma.
FDA OKs Leuprolide Mesylate 3-Month Formulation in Advanced Prostate Cancer
Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.
FDA Accepts New Drug Application for Gedatolisib in PIK3CA Wild-Type Breast Cancer
The rolling submission is supported by data from the PIK3CA wild-type cohort of the phase 3 VIKTORIA-1 trial evaluating gedatolisib in advanced breast cancer.
FDA Grants 2 Fast Track Designations to TT125-802 in EGFR/KRAS G12C NSCLC
TT125-802 monotherapy shrank the tumors in 5 of 7 patients with drug-resistant NSCLC, and no thrombocytopenia was observed.
